Be willing to not start or stop any NSAID or disease modifying treatments for SLE during the study
Be wiling to not use any legal or illegal cannabinoids, including FDA-approved cannabinoids during study participation
If female of child-bearing potential must be willing to use highly effective contraception during study participation
Treatment with steroids in the past 28 days
Actively listed on organ transplant list or have received an organ transplant other than a corneal transplant
Have active or chronic infections
Have a history of cancer (except cervical treated successfully with curative therapy or basal cell carcinoma)
Have a history of significant heart disease

Between the ages of 30-65
Able and willing to undergo an MRI
Able to travel to State College for the Study
Current psychotherapy treatment for depression
Started anti-depressant medication in the last 2 months
Diagnosis of bipolar disorder, schizophrenia, or significant neurocognitive impairment
Very severe depression that would interfere with the ability to participate or suicidal ideations
Unable to undergo an MRI (metal in your body)

Hemophilia A
FVIII Level <1% or 1-2% with> 10 bleeds past 52 weeks or 1-2% on prophy treatment
Greater than 150 exposure days to Factor VIII concentrate or cryo
No evidence of Factor VIII Inhibitor
Acceptable lab values as defined by protocol
Active Hep B or C &/or current antiviral therapy for Hep B or C
Significant underlying liver disease
HIV-1 or HIV-2 with CD4 count </=l to 200
Other investigational product in the past 12 weeks or gene therapy research within the past 52 weeks
Any other significant condition/disease that in the opinion of the investigator would make the subject unsuuitable

Premenopausal female aged 18 to 50 years old
Has a diagnosis of endometriosis verified by surgery in the last 10 years
Has regular menstrual cycles (21 to 35 days long)
Has moderate, severe, or very severe pain during menstrual cycles
Is not expected to undergo gynecological surgery (or other surgical procedures for treatment of endometriosis) during the study
Has a history of chronic pelvic pain that is not caused by endometriosis
Has had 4 or more prior laparoscopic, surgical, or other invasive procedure for endometriosis
Has had gynecological surgery or other surgical procedures for treatment of endometriosis within the 3 months prior to the Screening visit
Has unexplained vaginal bleeding outside of the patient’s regular menstrual period or pregnancy
Has a gastrointestinal disorder affecting absorption or gastrointestinal motility, history of or currently has osteoporosis or a systemic autoimmune disease

Children between the ages of 5 and 12
Children diagnosed with ADHD or suspected ADHD Symptoms
Children who are able to stop ADHD medication for testing days
Parent/child fluent in English
Children younger than 5 year or older than 12 years
Children with visual or hearing deficits or sensitivity to loud noise
Neurological conditions such as active seizure disorder
Prominent traits or diagnosis of Autism, marked developmental delay, mania, psychoses, or suicidal ideation.

12-23 years old
<250 lbs
First-degree relative diagnosed with Bipolar I Disorder
Less than 20/40 far acuity (corrected or uncorrected)
Neurological injury or disease
Pregnant women
Current substance dependence

Journalism student
Involvement on student newspaper
Involvement with other student media
No involvement in student journalism

Female, age of 18 years or older
Cytology confirmed primary invasive breast cancer, ductal carcinoma in situ or a combination of both
Scheduled for lumpectomy for a breast malignancy
No uncontrolled serious medical problems
Subjects who are pregnant at the time of breast cancer diagnosis
Uncontrolled hypertension or other uncontrolled medical problems
Patient who is sexually active and not willing to use contraception-hormonal or barrier method, or abstinence for 60 days after injection
Individuals undergoing a second lumpectomy because of previous positive margins
Subjects who have taken an investigational drug in the 30 days prior to enrollement

Children aged 8-12
Children outside of the 8-12 age range
History of seizures or photosensitive epilepsy

Medical assistance or low-income
child age 11 or 12 years
able to commit to two year study
able to read and write English
intellectual disability
cancer or congestive heart failure

Patient must have a subjective memory concern as reported by patient, study partner, or clinician
Age 55-90 (inclusive)
Study Partner is available who has frequent contact with the patient (e.g. an average of 10 hours per week or more), and can accompany the patient to most visits to answer questions about the patient
Must speak English fluently
Good general health with no additional diseases/disorders expected to interfere with the study
Any use of tobacco or nicotine products within the past year
Any significant neurologic disease such as Alzheimer’s disease dementia, Parkinson’s disease, multi-infarct dementia, brain tumor, seizure disorder, etc.
History of alcohol or substance abuse or dependence within the past 2 years

Adult (30-75)
Cancer diagnosis stage 0 through 3
Completed primary cancer treatment at least 3 months prior to participating
Have a scheduled or plan to schedule a follow-up cancer screening appointment in the next 30 days
Fluent in English
No cancer diagnosis, or diagnosis of Stage 4 cancer
Under the age of 30 or over the age of 75
Diagnosis of psychiatric disorder AND recent hospitalization
Visual impairments that would prevent use of mobile device or computer use
Severe cognitive impairment

Adults & Children 12 years or older
Diagnoses with HAE Type 1 or Type 2
2 or more HAE attacks per month
Pregnant females or planning on becoming pregnant or nursing
Anticipated use of short-term prophylaxis for pre-planned procedure or surgery
Chest pain, heart attack, passing out or significant heart beat abnormality
Pacemaker or defibrillator implanted
Family history of sudden cardiac death not related to HAE

Diagnosis of ulcerative colitis for at least 90 days
Failure or intolerance of biologic medications
Extensive colitis or pancolitis more than 10 years duration
Abdominal abscess or fulminant colitis at screening
Toxic megacolon at screening
Have any type of ostomy
Anticipating surgical intervention for UC
Fecal transplant within past 6 months

Over the age of 18
Have a basic proficiency of English
Physically able
Under the age of 18
Physically unable to climb stairs

>= age 13
read and speak English
neurological disorders
developmental disorders
Autism

Speak sentence length English as primary language
Normal or corrected to normal vision
Normal hearing
Individuals with and without an autism spectrum disorder or Asperger syndrome
Willing to consent and complete study requirements
Cannot speak sentence length English
Vision problems (uncorrected)
Hearing problems
Significant learning problems
Unwilling to consent or complete study requirements

Over the age of 18
Physically and mentally able
Basic proficiency of english
Under the age of 18
Unwilling to have video footage of the experiment taken

aged 18 – 24
able to speak and understand English language fluently
able to provide written informed consent
engaged in sexual activity in the past 6 months
fit into either study Group I (self-initiated STI testing) or Group II (never tested for STI) or Group III (Clinician-initiated)
Not meeting all the inclusion criteria

Age 18-60 years
Obesity (defined as body mass index between 30-40 kg/m2)
Hypertension (defined as seated blood pressure greater than 130/80 mmHg)
Able and willing to give informed consent
Pregnant or breastfeeding women
Current smokers
Type I or type II diabetes
History of major cardiovascular disease, immune or liver diseases, impaired renal or liver function
Age less than 18 years or greater than 60 years

Female adults 18 years and above with an adolescent child aged 13-16 years
Capacity for informed consent
Fluent in verbal and written English
Adolescent between the ages of 13 and 16 years (inclusive)
Diagnosis of autism spectrum disorder, substance use disorders, schizophrenia or other psychotic disorder
Any hearing or visual impairments
Investigator discretion regarding ability to participate in the study

Women within 1-5 years following menopause
Individuals taking hormone therapy
Individuals with resting blood pressure > or = 130/80 mmHg
Users of any tobacco and/or nicotine products (smokers, chewing tobacco, nicotine-containing patches/gum, smokeless cigarettes)
Individuals with any overt cardiovascular, metabolic, hematologic, pulmonary, renal, musculoskeletal, and/or neurological disease(s)

Symptoms consistent with Crohn's disease for at least 3 months
Inadequate response or loss of response to Crohn's treatment
At high risk for cancer of the colon
Has other diagnosis of colon disease(s)
Have an ostomy
History of extensive small bowel resection
Suspected infection of abdomen that has not been treated
Significant cardiovascular disease

Age > 18 years
Suspected or confirmed infection
Sepsis induced hypotension
> 4 hours from start of hypotension
> 3 L intravenous fluids
Pregnancy
Severe volume depletion
Immediate surgical intervention planned

Pretens 11 or 12 years old
Not vaccinated with the HPV vaccine
Have computer, tablet, or smartphone
Having received the HPV vaccine

Newly Diagnosed higher risk RCC of any histology
No clinical or radiological evidence of distant metastases
No concurrent or prior systemic or local anti-cancer therapy for RCC is permitted
Age must be greater than or equal to 18 years old
ECOG Performance status must be 0 or 1
Women must not be pregant or breast feeding
History of RCC that was resected with curative intent within the past 5 years
Prior or current prostate cancer is excluded
Active known or suspected autoimmune disease
Uncontrolled adrenal insufficiency

>25 years of age
not currently eating >2 avocados per month
increased waist circumference (35+ inches for women, 40+ inches for men)
does not eat or is allergic to avocados
not willing to undergo MRI scans
unstable medical conditions
lost/gained 10 or more pounds in past year

Must primarily speak and use English.
Must be a member of a dating couple, in which the members of the couple sent their first text messages to each other within the past year.
Must be able to bring a dating partner to the research lab.
Participants and their dating partner must reside at PSU or in the State College, PA area.
Participants and their dating partner must use iPhones, and at least one member of the couple must have Messages set up on their Mac laptop.
A person is not eligible for the study if they do not fit the inclusion criteria.

At least 18 years old
Subjects must have a history of primary brain tumor (including but not limited to glioblastoma (GBM), anaplastic astrocytoma (AA), anaplastic ganglioglioma (AG), and anaplastic pleomorphic xanthoastrocytoma (PXA)).
Subjects must have a BRAF-V600 mutation identified in previous tissue analysis (may be IHC or PCR based). Allowable mutations include V600E, V600K, V600R, and V600D.
Subjects must be taking dabrafenib at a dose of at least 50mg twice daily (adults only) and / or trametinib at a dose of at least 1mg daily (adults only) for at least 7 days prior to surgery as prescribed by their treating physician.
Subjects must be undergoing surgery for clinical purposes
Younger than 18 year old
Subjects who are receiving any other investigational agents or chemotherapeutic agents.

Healthy Individuals 18 years or older
Athletes (soccer, football, other) 18 years or older
Patient with ACL injury
Patient with ACL surgery
Pregnant women
Cognitive deficits
17 years old or younger